Tofflon

Tofflon (stock code: 300171), founded in 1993 and listed on the ChiNext board in 2011, is headquartered in Shanghai. It is a total solution provider for global pharmaceutical companies, offering process services, consumables, core equipment, and engineering solutions. Tofflon adheres to the core value of "Heaven rewards the diligent" and the mission of "serving biomedicine with professional technology," advancing steadily under the development strategy of "systematization, internationalization, and digital intelligence." Tofflon has four core business divisions: Bioprocess Division, Formulation Equipment Division, Engineering Division, and Food Engineering Division. To date, it has 26 domestic wholly-owned subsidiaries, including Tofflon Life Science and Tofflon Dehui, and 13 overseas wholly-owned subsidiaries, with 8 manufacturing bases in China and abroad. It operates three global R&D centers in China, the United States, and Germany. Tofflon continuously strengthens research in drug manufacturing science and pharmaceutical machinery science, striving to build the "next-generation drug manufacturing platform" and provide professional solutions for customers in R&D, pilot-scale, and commercial production, facilitating rapid drug development and large-scale commercial manufacturing. Tofflon has over 16,000 sets of equipment and systems serving more than 3,000 world-renowned pharmaceutical enterprises in over 50 countries and regions. After more than 30 years of development, Tofflon possesses leading R&D and design capabilities in the pharmaceutical equipment field, having obtained over 2,000 patented technologies and over 200 software copyrights. It is a leading enterprise in the global pharmaceutical equipment systematized product chain, the world's largest freeze dryer manufacturing base, and the manufacturer of the world's first workshop and equipment for inactivated COVID-19 vaccine production. Partial honors received by Tofflon Science and Technology Group: listed among Shanghai's Top 100 Enterprises for High-Tech Achievement Commercialization Projects; one of Shanghai's Most Dynamic Technology Enterprises (growth-oriented); Shanghai Science and Technology Enterprise Innovation Award; one of Shanghai's Top 100 Private Manufacturing Enterprises; one of Shanghai's Top 100 Private Enterprises; one of Shanghai's Top 100 Emerging Industry Enterprises; ranked in Shanghai's TOP 100 Hardcore Technology Enterprises; one of Shanghai's Top 100 Manufacturing Enterprises; First Prize for Scientific and Technological Achievements in China's Pharmaceutical Equipment; AAA-level Enterprise Credit Rating by the China Pharmaceutical Equipment Engineering Association; one of China's Top 100 Pharmaceutical Industry Enterprises; National Enterprise Technology Center. In the future, Tofflon will continue to uphold the mission of "serving biomedicine with professional technology," explore "innovative drug manufacturing models," create "advanced drug manufacturing platforms," and strive to grow from a "system solution provider" to a "deliverer of smart pharmaceutical factories," from "China's Tofflon" to "the world's Tofflon," serving the global pharmaceutical industry and contributing our wisdom and strength to the cause of human health. Special notice: During the recruitment process, our company never requests job seekers to transfer money or pay any fees, nor does it require candidates to undergo trial work before joining, or download or register software or accounts. All interviews are conducted in the company's office premises or through official video conferencing platforms (typically Tencent Meeting). Offer letters are issued via the "2号人事部" system, and the reporting address in the offer is always the company's official address, searchable on mainstream mapping software such as Amap and Baidu Maps. Job seekers are advised to remain vigilant and jointly maintain a trustworthy recruitment environment!